Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Leukocytes01:27

Disorders of Leukocytes

2.3K
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
2.3K
Disorders of Erythrocytes01:27

Disorders of Erythrocytes

2.6K
Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
2.6K
Humoral Immune Responses01:36

Humoral Immune Responses

85.3K
Overview
85.3K
Autoimmune Disorders01:29

Autoimmune Disorders

2.1K
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
2.1K
B Cell Activation and Differentiation01:24

B Cell Activation and Differentiation

17.7K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
17.7K
Disorders of Hemostasis01:24

Disorders of Hemostasis

2.6K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-world outcomes of plasmablastic lymphoma: Treatment approaches and survival outcomes in the PLASMABLAT-001 cohort.

Leukemia research·2026
Same author

Plasmablastic Lymphoma: 2026 Update on Diagnosis, Risk Stratification, and Management.

American journal of hematology·2026
Same author

Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial.

The Lancet. Haematology·2026
Same author

Zanubrutinib and pirtobrutinib show synergistic killing and suppression of BTK signaling in MYD88-mutated lymphoma cells.

Blood advances·2026
Same author

Prognosis and treatment of plasmablastic lymphoma in the United States: a multicenter retrospective study.

Blood cancer journal·2026
Same author

Final Report of a Phase II Study of Ibrutinib and Venetoclax in Previously Untreated Waldenström Macroglobulinemia.

American journal of hematology·2026
Same journal

Primary Care at the Center of America's Mental Health Landscape.

Primary care·2026
Same journal

We Care, and We Will Listen.

Primary care·2026
Same journal

Addressing Sexual Health in Primary Care.

Primary care·2026
Same journal

Diagnosis and Management of Eating Disorders in Adolescents and Young Adults.

Primary care·2026
Same journal

Management of Concomitant Mental Health Conditions in Older Adults with Cognitive Impairment.

Primary care·2026
Same journal

Nonpharmacologic Management of Insomnia Disorder in Primary Care.

Primary care·2026
See all related articles

Related Experiment Video

Updated: Mar 11, 2026

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells
10:26

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells

Published on: January 20, 2019

13.2K

Plasma Cell Disorders.

Jorge J Castillo1

  • 1Division of Hematological Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Mayer 221, Boston, MA 02215, USA.

Primary Care
|November 22, 2016
PubMed
Summary
This summary is machine-generated.

Advances in understanding plasma cell disorders have led to novel therapies. New treatments like proteasome inhibitors and monoclonal antibodies improve patient response and survival rates for these heterogeneous conditions.

Keywords:
AmyloidosisMGUSMultiple myelomaPOEMSWaldenström macroglobulinemia

More Related Videos

Flow Cytometric Characterization of Murine B Cell Development
08:25

Flow Cytometric Characterization of Murine B Cell Development

Published on: January 22, 2021

19.1K
Fluorescence-activated Cell Sorting for Purification of Plasmacytoid Dendritic Cells from the Mouse Bone Marrow
08:01

Fluorescence-activated Cell Sorting for Purification of Plasmacytoid Dendritic Cells from the Mouse Bone Marrow

Published on: November 4, 2016

13.1K

Related Experiment Videos

Last Updated: Mar 11, 2026

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells
10:26

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells

Published on: January 20, 2019

13.2K
Flow Cytometric Characterization of Murine B Cell Development
08:25

Flow Cytometric Characterization of Murine B Cell Development

Published on: January 22, 2021

19.1K
Fluorescence-activated Cell Sorting for Purification of Plasmacytoid Dendritic Cells from the Mouse Bone Marrow
08:01

Fluorescence-activated Cell Sorting for Purification of Plasmacytoid Dendritic Cells from the Mouse Bone Marrow

Published on: November 4, 2016

13.1K

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Plasma cell disorders encompass a spectrum of benign, premalignant, and malignant conditions.
  • These disorders are defined by the presence of monoclonal paraproteins in serum or urine.
  • Significant biological, pathological, and clinical heterogeneity exists within plasma cell disorders.

Purpose of the Study:

  • To review recent advancements in understanding the biology of plasma cell disorders.
  • To highlight the development and impact of novel therapeutic agents.
  • To discuss the improved clinical outcomes associated with new treatment strategies.

Main Methods:

  • Review of recent scientific literature on plasma cell disorder biology and therapeutics.
  • Analysis of approved novel agents including proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies.
  • Evaluation of clinical response rates, survival data, and toxicity profiles of new therapies.

Main Results:

  • Major advances in understanding disease biology are driving therapeutic innovation.
  • Novel agents (proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies) are approved.
  • These therapies demonstrate higher response and survival rates with improved toxicity profiles.

Conclusions:

  • Novel therapeutic agents represent a significant advancement in managing plasma cell disorders.
  • Improved understanding of disease mechanisms facilitates the development of targeted treatments.
  • Current therapies are enhancing patient outcomes and quality of life.